StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research note released on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright restated a buy rating and issued a $9.00 price target on shares of Trevena in a research report on Tuesday, April 2nd.
Get Our Latest Stock Analysis on Trevena
Trevena Trading Down 1.8 %
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC purchased a new position in Trevena, Inc. (NASDAQ:TRVN – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena at the end of the most recent quarter. 13.56% of the stock is owned by hedge funds and other institutional investors.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading
- Five stocks we like better than Trevena
- How to Effectively Use the MarketBeat Ratings Screener
- High-Yield Texas Instruments Could Hit New Highs Soon
- Basic Materials Stocks Investing
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- How to Invest in the Best Canadian Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.